Assam Chief Minister Himanta Biswa Sarma met the "Team Europe" EU delegation to boost trade and investment. The two-day visit focuses on se...

Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Specialty chemicals maker Anupam Rasayan India is set to acquire up to 43.3% of Bliss GVS Pharma for an estimated Rs 1,369.51 crore, with a...

Investors are increasingly betting that “China is back” as the economy rebounds from years of deflation, helped by strong manufacturing, ex...

Markets extended their rebound for a second consecutive session on Thursday, buoyed by supportive global cues and selective buying in heavy...

Indian stock markets are experiencing a significant rally. The BSE Sensex and Nifty 50 indices have climbed over 1 percent each. This surge...

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

Sun Pharma has acquired Organon & Co for $11.75 billion. This deal provides Sun Pharma with expanded global scale and commercial reach. It ...

Sun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...

The company said 51% of its revenue came from finished dosages, which is its biggest business. Active pharmaceuticals ingredients and pharm...

Consolidated revenue stood at Rs 2,555.04 crore against Rs 2,203.66 crore in the year-ago period.

The company had posted a net profit of Rs 223.58 crore for the corresponding period of the previous fiscal, Glenmark Pharmaceuticals said i...

Glenmark Pharmaceuticals reported a consolidated net profit of Rs 10.61 crore for the fourth quarter ended March 31, 2015.